For the millions of adults living with fatty liver disease, the absence of cirrhosis has long been mistakenly equated with low cancer risk. This large-scale analysis challenges that assumption directly, offering a practical, non-invasive tool to identify who warrants closer surveillance — before fibrosis reaches its most dangerous stage.
Drawing on the Veterans Analysis of Liver Disease (VALID) cohort, investigators followed 30,414 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) over nearly 70,000 person-years, tracking hepatocellular carcinoma (HCC) incidence against transient elastography readings. Each 5 kPa increment in liver stiffness measurement (LSM) corresponded to an 18% increase in HCC risk (subdistribution hazard ratio: 1.18, 95% CI: 1.14–1.21). Annual HCC incidence climbed from 0.34 per 100 person-years at an LSM of 10–14.9 kPa to 0.94 per 100 person-years at 25 kPa or above. Critically, a subgroup without cirrhosis or clinically significant portal hypertension but with both diabetes and an LSM ≥10 kPa still exceeded the 0.46 per 100 person-year threshold generally considered cost-effective for formal HCC surveillance programs.
This finding carries considerable clinical weight because standard HCC surveillance guidelines have historically anchored around cirrhosis as the primary trigger — leaving a meaningful proportion of MASLD patients in a surveillance gap. Previous studies have estimated that roughly one-third of MASLD-related HCC cases arise in non-cirrhotic livers, making the identification of intermediate-risk subgroups an urgent unmet need. Transient elastography is already widely deployed in hepatology practice, meaning LSM-based stratification could be implemented without new infrastructure. Key limitations include the retrospective, predominantly male Veterans Affairs population, which may limit generalizability to women and non-veteran demographics. The study is also observational, so causal interpretation requires caution. Nonetheless, the large cohort size and dose-response relationship between LSM and HCC incidence lend this analysis more than incremental value — it provides an actionable, quantitative framework for risk-tiered surveillance in MASLD.